# Martha Mayo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/martha-mayo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,076 |
| Field | Potassium and Related Disorders |
| h-index | 22 |
| i10-index | 29 |
| Last Known Institution | University of Connecticut |
| OpenAlex ID | https://openalex.org/A5108493061 |
| Works | 67 |

## Researcher papers

- [Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors](https://scholariq.org/papers/patiromer-in-patients-with-kidney-disease-and-hyperkalemia-receiving-raas/)
- [Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS](https://scholariq.org/papers/intrathecal-ziconotide-in-the-treatment-of-refractory-pain-in-patients-with/)
- [Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease](https://scholariq.org/papers/effect-of-patiromer-on-serum-potassium-level-in-patients-with-hyperkalemia-and/)
- [Alzheimer's disease, normal‐pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis](https://scholariq.org/papers/alzheimer-s-disease-normal-pressure-hydrocephalus-and-senescent-changes-in-csf/)
- [Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/patiromer-versus-placebo-to-enable-spironolactone-use-in-patients-with-resistant/)
- [Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial](https://scholariq.org/papers/intrathecal-ziconotide-in-the-treatment-of-chronic-nonmalignant-pain-a/)
- [Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors](https://scholariq.org/papers/effect-of-patiromer-on-reducing-serum-potassium-and-preventing-recurrent/)
- [Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis](https://scholariq.org/papers/peginesatide-for-anemia-in-patients-with-chronic-kidney-disease-not-receiving/)
- [Peginesatide in Patients with Anemia Undergoing Hemodialysis](https://scholariq.org/papers/peginesatide-in-patients-with-anemia-undergoing-hemodialysis/)
- [Assessment of low-flow CSF drainage as a treatment for AD](https://scholariq.org/papers/assessment-of-low-flow-csf-drainage-as-a-treatment-for-ad/)
- [Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure](https://scholariq.org/papers/patiromer-versus-placebo-to-enable-spironolactone-use-in-patients-with-resistant-2/)
- [Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors](https://scholariq.org/papers/effect-of-patiromer-on-hyperkalemia-recurrence-in-older-chronic-kidney-disease/)

## Researcher topics

- [Potassium and Related Disorders](https://scholariq.org/topics/potassium-and-related-disorders/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Electrolyte and hormonal disorders](https://scholariq.org/topics/electrolyte-and-hormonal-disorders/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)

## Researcher university

- [University of Connecticut](https://scholariq.org/institutions/university-of-connecticut/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.